A Candidate New Disease
RedShoulder, thank you for that clear re-stating of Missling's comments. So very helpful. So much good stuff happening.
With personal interest and expertise, I noted noted this statement:
"We have other indications that we have not mentioned yet."
Of course, because of blarcamesine's optimization, activation of the sigma-1 receptor protein, which thereby enables the cell to restore or strengthen a diversity of homeostatic processes (all of which allow proper cell physiology) --- the MOA (mechanism of action, the drug will have applications for any number of diseases yet to be discovered. In a few years, Anavex and blarcamesine will be known for successfully treating not just a few CNS diseases but an ever-widening spectrum health conditions.
As in the past, I'll once again predict one new rare disease for blarcamesine; one that I have, in a mild, only slightly debilitating form: hereditary spastic paraplegia (HSP). There are several dozen genotypes of the disease, varying in severity. But in all cases, motor neurons, controlling muscles, lack sufficient levels of gamma-aminobutyric acid, GABA. With that deficiency muscle-controlling nerves become hyperexcited and fire continuously. The attached muscles are continually contracted; are spastic.
In a hard-drive failure I lost my copy of an obscure paper that showed HSP-model rats, rats with an inserted human HSP gene, were able to walk normally after drinking water than had Anavex 2-73 in it; in just a few days of such therapy. Blarcamesine was shown to optimize or increase GABA levels in girls with Rett syndrome.
Consequently, HSP may well be one of Missling's diseases "not mentioned yet." If it's not, it should on his ever-widening list. I'm eager to be a test subject in a clinical trial of blarcamesine for HSP. If I'm not stuck in the placebo arm, I'll be able to get rid of my walker and gait about with normal ease.
AI
Market Data 
Markets 
